Compare Stocks: RGNX, ZYME, XNCR, and MESO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MESO Mesoblast	$14.75 -0.8%	$15.92	$13.05 ▼ $21.50	$1.92B	2.12	225,436 shs	46,024 shs
RGNX REGENXBIO	$7.66 +2.8%	$9.41	$5.45 ▼ $16.19	$505.97M	0.94	1.43 million shs	489,696 shs
XNCR Xencor	$25.70 +2.8%	$24.00	$10.38 ▼ $30.61	$1.91B	0.88	956,767 shs	241,683 shs
ZYME Zymeworks	$27.43 +0.8%	$26.13	$16.00 ▼ $31.34	$1.95B	1.19	687,311 shs	208,701 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MESO Mesoblast	+2.55%	-6.60%	-14.74%	+5.54%	-7.18%
RGNX REGENXBIO	-0.27%	-8.59%	-22.88%	-43.09%	-24.37%
XNCR Xencor	-2.34%	-0.64%	-4.07%	+62.55%	+116.45%
ZYME Zymeworks	+0.29%	-1.34%	-3.78%	+5.75%	+57.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MESO Mesoblast	$14.75 -0.8%	$15.92	$13.05 ▼ $21.50	$1.92B	2.12	225,436 shs	46,024 shs
RGNX REGENXBIO	$7.66 +2.8%	$9.41	$5.45 ▼ $16.19	$505.97M	0.94	1.43 million shs	489,696 shs
XNCR Xencor	$25.70 +2.8%	$24.00	$10.38 ▼ $30.61	$1.91B	0.88	956,767 shs	241,683 shs
ZYME Zymeworks	$27.43 +0.8%	$26.13	$16.00 ▼ $31.34	$1.95B	1.19	687,311 shs	208,701 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MESO Mesoblast	+2.55%	-6.60%	-14.74%	+5.54%	-7.18%
RGNX REGENXBIO	-0.27%	-8.59%	-22.88%	-43.09%	-24.37%
XNCR Xencor	-2.34%	-0.64%	-4.07%	+62.55%	+116.45%
ZYME Zymeworks	+0.29%	-1.34%	-3.78%	+5.75%	+57.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MESO Mesoblast	2.33	Hold	$39.00	164.41% Upside
RGNX REGENXBIO	2.62	Moderate Buy	$23.27	204.02% Upside
XNCR Xencor	2.64	Moderate Buy	$34.00	32.31% Upside
ZYME Zymeworks	2.77	Moderate Buy	$40.45	47.51% Upside

Current Analyst Ratings Breakdown

Latest RGNX, ZYME, XNCR, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
9/29/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$38.00 ➝ $39.00
9/29/2026	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$34.00
9/28/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/28/2026	XNCR Xencor	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$27.00 ➝ $29.00
9/24/2026	MESO Mesoblast	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	XNCR Xencor	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	XNCR Xencor	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$20.00 ➝ $26.00
9/17/2026	ZYME Zymeworks	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/11/2026	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$27.00 ➝ $35.00
9/4/2026	RGNX REGENXBIO	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MESO Mesoblast	$120.25M	15.93	N/A	N/A	$4.38 per share	3.37
RGNX REGENXBIO	$170.44M	2.96	N/A	N/A	$2.03 per share	3.77
XNCR Xencor	$104.97M	18.20	N/A	N/A	$8.90 per share	2.89
ZYME Zymeworks	$37.13M	52.42	N/A	N/A	$3.59 per share	7.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MESO Mesoblast	-$57.50M	-$0.28	N/A	40.97	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	-$193.88M	-$3.79	N/A	N/A	N/A	-112.58%	-220.07%	-46.04%	11/5/2026 (Estimated)
XNCR Xencor	-$91.92M	-$2.17	N/A	N/A	N/A	-155.59%	-28.66%	-20.38%	11/4/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	53.77	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest RGNX, ZYME, XNCR, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/6/2026	Q2 2026	RGNX REGENXBIO	$0.0787	$0.43	+$0.3513	$0.43	$97.63 million	$108.02 million
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MESO Mesoblast	0.19	2.43	2.09
RGNX REGENXBIO	N/A	2.86	2.86
XNCR Xencor	N/A	6.39	6.39
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MESO Mesoblast	1.43%
RGNX REGENXBIO	88.08%
XNCR Xencor	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
MESO Mesoblast	18.80%
RGNX REGENXBIO	14.22%
XNCR Xencor	5.08%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MESO Mesoblast	108	129.88 million	105.46 million	Optionable
RGNX REGENXBIO	371	66.01 million	56.63 million	Optionable
XNCR Xencor	260	74.35 million	70.58 million	Optionable
ZYME Zymeworks	264	70.96 million	47.18 million	N/A

RGNX, ZYME, XNCR, and MESO Headlines

Recent News About These Companies

Copertura su Zymeworks ripristinata con Buy da TD Cowen sull’acquisizione

September 29 at 3:20 PM | it.investing.com

Zymeworks (NASDAQ:ZYME) Stock Rated "Buy" in New Coverage at TD Cowen

September 29 at 11:05 AM | marketbeat.com

Zymeworks raises 2026 guidance after closing Theravance acquisition

September 28 at 3:17 PM | streetinsider.com

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

September 28 at 3:17 PM | finance.yahoo.com

Zymeworks Inc. Updates Earnings Guidance for the Year 2026

September 28 at 12:47 PM | marketscreener.comM

Zymeworks Appoints Stuart Knight as Executive Vice President & Chief Information Officer

September 28 at 12:47 PM | marketscreener.comM

Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow

September 28 at 9:01 AM | seekingalpha.com

Zymeworks Issues Updated 2026 Financial Guidance

September 28 at 7:46 AM | rttnews.com

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

September 28 at 6:00 AM | globenewswire.com

Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME

September 28 at 3:19 AM | marketbeat.com

Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger

September 26, 2026 | kalkinemedia.comK

Vancouver biotech Zymeworks closes US$929M Theravance deal

September 24, 2026 | vancouverisawesome.comV

Zymeworks Completes Acquisition of Theravance Biopharma

September 23, 2026 | globenewswire.com

Head-To-Head Survey: Zymeworks (NASDAQ:ZYME) & Alnylam Pharmaceuticals (NASDAQ:ALNY)

September 23, 2026 | americanbankingnews.com

Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME

September 22, 2026 | marketbeat.com

Zymeworks stock gains on fresh Wolfe Research coverage

September 21, 2026 | ad-hoc-news.deA

Zymeworks stock gains on merger approval and a $41 target

September 20, 2026 | ad-hoc-news.deA

Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts

September 20, 2026 | americanbankingnews.com

Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages

September 20, 2026 | marketbeat.com

Theravance Shareholders Approve Merger with Zymeworks Inc.

September 18, 2026 | tipranks.com

Wolfe Research Begins Coverage on Zymeworks (NASDAQ:ZYME)

September 17, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, ZYME, XNCR, and MESO Company Descriptions

Mesoblast NASDAQ:MESO

$14.75 -0.12 (-0.81%)

As of 01:16 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

REGENXBIO NASDAQ:RGNX

$7.66 +0.21 (+2.75%)

As of 01:17 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Xencor NASDAQ:XNCR

$25.70 +0.70 (+2.79%)

As of 01:17 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Zymeworks NASDAQ:ZYME

$27.42 +0.23 (+0.83%)

As of 01:16 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGNX, ZYME, XNCR, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGNX, ZYME, XNCR, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGNX, ZYME, XNCR, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, ZYME, XNCR, and MESO Company Descriptions

Mesoblast NASDAQ:MESO

REGENXBIO NASDAQ:RGNX

Xencor NASDAQ:XNCR

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGNX, ZYME, XNCR, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGNX, ZYME, XNCR, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGNX, ZYME, XNCR, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, ZYME, XNCR, and MESO Company Descriptions

Mesoblast NASDAQ:MESO

REGENXBIO NASDAQ:RGNX

Xencor NASDAQ:XNCR

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools